ORY.MC BME
Oryzon Genomics S.A.
1W: +0.0%
1M: -2.9%
3M: -7.8%
YTD: -13.1%
1Y: +2.2%
3Y: +33.2%
5Y: -15.7%
€2.73 ($3.07)
-0.02 (-0.80%)
Weekly Expected Move ±2.5%
€3
€3
€3
€3
€3
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$0
-100.0% ▼
Gross Profit
-$134K
-101.9% ▼
Operating Income
-$6M
-45.1% ▼
Net Income
-$3M
+28.9% ▲
EPS (Diluted)
$-0.04
+38.5% ▲
EBITDA
-$6M
-41.7% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $11M | $0 | $0 | $7M | $0 |
| YoY Growth | +11.5% | -100.0% | +0.0% | +0.0% | -100.0% |
| Cost of Revenue | $746K | -$15M | $244K | $302K | $134K |
| Gross Profit | $10M | $15M | $14M | $7M | -$134K |
| Gross Margin | 93.0% | — | — | 95.9% | — |
| R&D Expenses | $7M | $7M | $6M | $0 | $13M |
| SG&A Expenses | $13M | $18M | $4M | $3M | -$6M |
| Operating Expenses | $17M | $21M | $18M | $11M | $6M |
| Operating Income | -$7M | -$5M | -$5M | -$4M | -$6M |
| Operating Margin | -66.0% | — | — | -60.1% | — |
| Interest Expense | $456K | $1M | $2M | $1M | $608K |
| Income Before Tax | -$7M | -$7M | -$6M | -$6M | -$6M |
| Tax Expense | -$2M | -$2M | -$3M | -$2M | -$3M |
| Net Income | -$5M | -$4M | -$3M | -$4M | -$3M |
| Net Margin | -44.2% | — | — | -49.8% | — |
| EPS (Diluted) | $-0.09 | $-0.08 | $-0.06 | $-0.06 | $-0.04 |
| EBITDA | -$7M | -$5M | -$4M | -$4M | -$6M |
| Shares Outstanding | 53M | 56M | 61M | 64M | 74M |